{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:36:23Z","timestamp":1767141383600,"version":"build-2238731810"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10549-013-2810-9","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T08:33:00Z","timestamp":1386664380000},"page":"325-332","source":"Crossref","is-referenced-by-count":43,"title":["A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure"],"prefix":"10.1007","volume":"143","author":[{"given":"Suleiman","family":"Massarweh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Romond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther P.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Van Meter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Kadamyan-Melkumian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Elledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"issue":"9","key":"2810_CR1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y","volume":"92","author":"J Bonneterre","year":"2001","unstructured":"Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247\u20132258. doi: 10.1002\/1097-0142(20011101)92:9<2247:AID-CNCR1570>3.0.CO;2-Y","journal-title":"Cancer"},{"issue":"10","key":"2810_CR2","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","volume":"19","author":"H Mouridsen","year":"2001","unstructured":"Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19(10):2596\u20132606","journal-title":"J Clin Oncol"},{"issue":"18","key":"2810_CR3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jnci\/djj357","volume":"98","author":"D Mauri","year":"2006","unstructured":"Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98(18):1285\u20131291. doi: 10.1093\/jnci\/djj357","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"2810_CR4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6601629","volume":"90","author":"C Osborne","year":"2004","unstructured":"Osborne C, Wakeling A, Nicholson R (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2\u2013S6","journal-title":"Br J Cancer"},{"issue":"10","key":"2810_CR5","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664\u20131670. doi: 10.1200\/JCO.2007.13.5822","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"2810_CR6","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1677\/erc.1.01273","volume":"13","author":"S Massarweh","year":"2006","unstructured":"Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor\/growth factor signaling crosstalk. Endocr Relat Cancer 13(Supplement 1):S15\u2013S24. doi: 10.1677\/erc.1.01273","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2810_CR7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/bcr1763","volume":"9","author":"A Leary","year":"2007","unstructured":"Leary A, Sirohi B, Johnston S (2007) Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. Breast Cancer Res 9(5):112","journal-title":"Breast Cancer Res"},{"issue":"9","key":"2810_CR8","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-06-2466","volume":"13","author":"G Sabnis","year":"2007","unstructured":"Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A (2007) Inhibition of the phosphatidylinositol 3-kinase\/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 13(9):2751\u20132757. doi: 10.1158\/1078-0432.ccr-06-2466","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"2810_CR9","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1677\/erc.1.01018","volume":"12","author":"RJ Santen","year":"2005","unstructured":"Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J Jr, Berstein L, Yue W (2005) Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 12(Supplement 1):S61\u2013S73. doi: 10.1677\/erc.1.01018","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"2810_CR10","first-page":"5985","volume":"61","author":"M Sun","year":"2001","unstructured":"Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ (2001) Phosphatidylinositol-3-OH Kinase (PI3K)\/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61(16):5985\u20135991","journal-title":"Cancer Res"},{"issue":"8","key":"2810_CR11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","volume":"18","author":"M Beeram","year":"2007","unstructured":"Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 18(8):1323\u20131328. doi: 10.1093\/annonc\/mdm170","journal-title":"Ann Oncol"},{"issue":"2","key":"2810_CR12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2005.12.019","volume":"102","author":"O Treeck","year":"2006","unstructured":"Treeck O, Wackwitz B, Haus U, Ortmann O (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102(2):292\u2013299","journal-title":"Gynecol Oncol"},{"issue":"33","key":"2810_CR13","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","volume":"29","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452\u20134461. doi: 10.1200\/jco.2010.34.4879","journal-title":"J Clin Oncol"},{"issue":"7418","key":"2810_CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61\u201370. doi: 10.1038\/nature11412","journal-title":"Nature"},{"issue":"15","key":"2810_CR15","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","volume":"68","author":"K Stemke-Hale","year":"2008","unstructured":"Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo W-L, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung M-C, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084\u20136091. doi: 10.1158\/0008-5472.can-07-6854","journal-title":"Cancer Res"},{"key":"2810_CR16","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","volume":"30","author":"T Bachelot","year":"2012","unstructured":"Bachelot T (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO Study. J Clin Oncol 30:2718\u20132724","journal-title":"J Clin Oncol"},{"issue":"6","key":"2810_CR17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520\u2013529. doi: 10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"issue":"5","key":"2810_CR18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s10637-013-9991-2","volume":"31","author":"DM Hyams","year":"2013","unstructured":"Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar VM, Lombard J, Mookerjee B, Xu J, Brown K, Klein P (2013) Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs 31(5):1345\u20131354. doi: 10.1007\/s10637-013-9991-2","journal-title":"Invest New Drugs"},{"issue":"10","key":"2810_CR19","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/annonc\/mdt213","volume":"24","author":"WW Tan","year":"2013","unstructured":"Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA (2013) N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol 24(10):2548\u20132554","journal-title":"Ann Oncol"},{"issue":"3","key":"2810_CR20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(13)70026-3","volume":"14","author":"JF Robertson","year":"2013","unstructured":"Robertson JF, Ferrero JM, Bourgeois H, Kennecke H, de Boer RH, Jacot W, McGreivy J, Suzuki S, Zhu M, McCaffery I, Loh E, Gansert JL, Kaufman PA (2013) Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol 14(3):228\u2013235. doi: 10.1016\/S1470-2045(13)70026-3","journal-title":"Lancet Oncol"},{"key":"2810_CR21","doi-asserted-by":"crossref","unstructured":"Burstein HJ, Barry WT, Cirrincione C, Chew HK, Tolaney S, Lake D, Pluard T, Blackwell K, Winer EP, Hudis CA (2010) Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: a double-blinded, placebo-controlled, randomized phase III study. Cancer Res 70(24 Suppl 2):Abstr nr PD-05-01. doi: 10.1158\/0008-5472.SABCS10-PD05-01","DOI":"10.1158\/0008-5472.SABCS10-PD05-01"},{"issue":"3","key":"2810_CR22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10549-012-1997-5","volume":"133","author":"RW Carlson","year":"2012","unstructured":"Carlson RW, O\u2019Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW (2012) A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 133(3):1049\u20131056. doi: 10.1007\/s10549-012-1997-5","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"2810_CR23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/jnci\/87.10.746","volume":"87","author":"CK Osborne","year":"1995","unstructured":"Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI (1995) Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87(10):746\u2013750","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2810_CR24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","volume":"22","author":"A Howell","year":"2004","unstructured":"Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22(9):1605\u20131613. doi: 10.1200\/JCO.2004.02.112","journal-title":"J Clin Oncol"},{"issue":"16","key":"2810_CR25","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","volume":"20","author":"A Howell","year":"2002","unstructured":"Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396\u20133403","journal-title":"J Clin Oncol"},{"issue":"16","key":"2810_CR26","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","volume":"20","author":"CK Osborne","year":"2002","unstructured":"Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386\u20133395","journal-title":"J Clin Oncol"},{"issue":"30","key":"2810_CR27","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Leo Di","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JPO, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250\u00a0mg With fulvestrant 500\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594\u20134600. doi: 10.1200\/jco.2010.28.8415","journal-title":"J Clin Oncol"},{"issue":"10","key":"2810_CR28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"SR Johnston","year":"2013","unstructured":"Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM (2013) Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 14(10):989\u2013998. doi: 10.1016\/S1470-2045(13)70322-X","journal-title":"Lancet Oncol"},{"issue":"5","key":"2810_CR29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1056\/NEJMoa1201622","volume":"367","author":"RS Mehta","year":"2012","unstructured":"Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367(5):435\u2013444. doi: 10.1056\/NEJMoa1201622","journal-title":"N Engl J Med"},{"issue":"16","key":"2810_CR30","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, J\u00f6nsson P-E, Lidbrink EK, Trudeau M, Eiermann W, Brattstr\u00f6m D, Lindemann JPO, Wiklund F, Henriksson R (2012) FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30(16):1919\u20131925. doi: 10.1200\/jco.2011.38.1095","journal-title":"J Clin Oncol"},{"key":"2810_CR31","author":"AC Wolff","year":"2012","unstructured":"Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF (2012) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. doi: 10.1200\/jco.2011.38.3331","journal-title":"J Clin Oncol"},{"issue":"23","key":"2810_CR32","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","volume":"30","author":"NL Busaidy","year":"2012","unstructured":"Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL (2012) Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30(23):2919\u20132928. doi: 10.1200\/JCO.2011.39.7356","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s10549-015-3263-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T00:00:00Z","timestamp":1421798400000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2810-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2810-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2810-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T15:05:23Z","timestamp":1564931123000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2810"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2810-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,11]]}}}